Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and preventionAnil Desphande, Donald D. Muccio, Venkatram R. Atigadda et al.|Bioorganic & Medicinal Chemistry|2013Cited by 22
Methyl Substitution of a Rexinoid Agonist Improves Potency and Reveals Site of Lipid ToxicityVenkatram R. Atigadda, Donald D. Muccio, Clinton J. Grubbs et al.|Journal of Medicinal Chemistry|2014Cited by 21